Akers Biosciences Announces a Change to the Board of Directors
2018年5月29日 - 8:00PM
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio”
or the "Company"), a developer of rapid health information
technologies, announces that Raymond F. Akers Jr., Ph.D has
resigned as a director of the Company with immediate effect.
Pursuant to U.S. Federal Securities Laws, within
four business days the Company will file a Form 8-K with the
Securities and Exchange Commission, which may include further
information with respect to the resignation.
For more information:
Akers Biosciences, Inc.John J. Gormally, Chief
Executive OfficerTel. +1 856 848 8698
Vigo Communications (Global Public Relations)Ben
Simons / Fiona HensonTel. +44 (0)20 7830 9704Email:
akers@vigocomms.com
About Akers Biosciences,
Inc.
Akers Bio develops, manufactures, and supplies
rapid screening and testing products designed to deliver quicker
and more cost-effective healthcare information to healthcare
providers and consumers. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its
products can be found at www.akersbio.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward
Looking Statements
Statements contained herein that are not based
upon current or historical fact are forward-looking in nature and
constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such forward-looking statements reflect the
Company's expectations about its future operating results,
performance and opportunities that involve substantial risks and
uncertainties. The forward-looking statements include statements or
expectations regarding the effects on the Company due to the
resignation of Raymond F. Akers Jr., Ph.D from the Board of
the Company, other risks detailed in the Company's periodic reports
filed with the Securities and Exchange Commission and other future
events. When used herein, the words "anticipate," "believe,"
"estimate," "upcoming," "plan," "target", "intend" and "expect" and
similar expressions, as they relate to Akers Biosciences, Inc., its
subsidiaries, or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information currently available to the Company and are
subject to a number of risks, uncertainties, and other factors that
could cause the Company's actual results, performance, prospects,
and opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 9 2024 まで 10 2024
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 10 2023 まで 10 2024